A computerized infusion system was used to determine mivacurium infusion requirements to maintain 95% and 50% neuromuscular block in 1 5 infants less than 1 yr of age. Neuromuscular block was measured by adductor pollicis EMG and anaesthesia maintained with 66% nitrous oxide in oxygen and alfentanil 50-100 ug kg" 1 h"
Mivacurium, a short-acting, non-depolarizing neuromuscular blocking agent, has been studied to a small extent in infants [1] . Dose-response curves [2, 3] and infusion requirements [4] [5] [6] of mivacurium have been determined in children during both halothane and balanced anaesthesia. A common finding has been that requirements for mivacurium are greater in children than in adults. Results of the only infant study showed that the potency of mivacurium may be different, but infusion requirements were similar to those in children during halothane anaesthesia [1] . Our aim was to study the pharmacodynamics of mivacurium in infants of less than 1 yr of age by determining potency and infusion requirements of mivacurium to maintain 50% and 95% neuromuscular block during nitrous oxide-oxygenalfentanil anaesthesia.
Patients and methods
After obtaining approval of the Institutional Ethics Committee and informed parental consent, we studied 15 infants aged 1-11 months, ASA I or II, during elective surgery. All patients had been fullterm neonates. Duration of surgery was scheduled to exceed 90 min. Patients with renal or hepatic disease or those receiving any medications known to affect neuromuscular transmission were excluded.
Premedication comprised rectal methohexitone 15-20 mg kg" 1 . Anaesthesia was induced with alfentanil 50-100 ug kg" 1 and thiopentone 5-Smgkg" 1 . Patients breathed 66 % nitrous oxide in oxygen from induction to emergence from anaesthesia. During maintenance of anaesthesia, alfentanil was administered by a continuous infusion of 50-100 ug kg^1 IT 1 and thiopentone 1 mg kg" 1 was given as needed to deepen the level of anaesthesia. ECG, 5po 2 , non-invasive arterial pressure and palmar skin temperature (Cardiocap, Datex, Helsinki, Finland) were monitored throughout anaesthesia. Ventilation was controlled to maintain end-tidal carbon dioxide partial pressure at 5-5.5 kPa.
Neuromuscular transmission was monitored using an electromyograph (Relaxograph, Datex). Stimulating surface electrodes were attached over the ulnar nerve at the wrist and recording electrodes over the adductor pollicis muscle and volar surface of the base of the forefinger to receive an optimal EMG signal [7] . Train-of-four stimulation was applied every 20 s and calibration of the neuromuscular monitoring device was carried out 5-10 min after induction of anaesthesia. Thereafter, a stable baseline calibration signal was awaited before administration of mivacurium.
Each patient received a bolus dose of mivacurium 0.1 mg kg" 1 and the maximum neuromuscular effect following this dose was recorded. Thereafter, a second similar bolus dose was administered and the trachea was intubated when neuromuscular block (depression of the first EMG response in the trainof-four responses) remained greater than 90%. Thereafter, a closed-loop computer-controlled infusion of mivacurium was initiated [6] and the target neuromuscular block was set to 95 %. When at least 40 min of infusion time had elapsed, the target neuromuscular block was re-set to 50 % block and a second 40 min of infusion time was recorded. At the end of anaesthesia, residual neuromuscular block was allowed to recover spontaneously before removal of the tracheal tube.
Mean infusion requirements of mivacurium to maintain 95 % and 50 % neuromuscular block were analysed from computer recordings [6] . These infusion requirements were calculated on the basis of body weight (ug kg" 1 h" 1 ) and body surface area ((ig m" 2 h" 1 ). In addition, we determined the number of individual ED,, doses of mivacurium that would be required hourly to maintain 95 % neuromuscular block. For this purpose, an estimate of an individual ED,, dose was calculated on the basis of the maximum neuromuscular response after the initial 0.1-mg kg" 1 dose of mivacurium, using the method described previously [6, 8] : a point which represented the 0.1-mg kg" 1 dose and the maximum neuromuscular effect produced by this dose was plotted on log-probit paper on which parallel lines with a slope of 6.5 probit log" 1 were drawn. An estimated individual ED,5 dose of mivacurium was determined by analysing the dose required to produce 95% neuromuscular block when a line with a slope of 6.5 probit log" 1 was drawn via the one dose-response point determined for that individual patient [6, 8] ; 100% neuromuscular block was regarded as 8.0 probit response.
For statistical purposes, linear regression analysis and Student's t test for paired data were used, when appropriate. P < 0.05 was regarded as significant. All values are presented as mean (SD) unless otherwise stated. The computer maintained neuromuscular block within 85-99 % after 3 (2) min from initiation of the computer-controlled mivacurium infusion. Mean durations of mivacurium infusion for the two block levels were 44 (5) and 53 (18) min, respectively. One infant had a duration of surgery shorter than anticipated and her infusion requirements for 50 % neuromuscular block could not be analysed. The mean infusion requirement of mivacurium to maintain 95% neuromuscular block was 820 (300) Ug kg" 1 h" 1 or 15.6 (6.3) mg irr 2 h" 1 . This represents an hourly requirement of 6.6 (1.5) individual ED,, doses (table 1). The infusion requirements of mivacurium to maintain 50 % neuromuscular block was significantly less (P = 0.0001), notably 320 (150) ug kg" 1 h" 1 or 6.2 (3.0) mg nr 2 h~'.
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We have evaluated the pharmacodynamics of mivacurium in infants using a model-driven computerized infusion device to maintain two different levels of neuromuscular block. The infusion device was easy to use and resulted in relatively rapid control of the target neuromuscular block. If mivacurium infusion is adjusted by open model, frequent rate adjustments have been required during the first 15 min of infusion [1, 4, 5] . In the present study, achieving a stable neuromuscular response took only a few minutes, even less than in our previous study in 1-15 yr old children [6] . During nitrous oxide in oxygen and alfentanil anaesthesia, infants required a mean rate of mivacurium 820 ug kg" 1 h" 1 (14 ug kg" 1 min" 1 ) to maintain 95 % neuromuscular block. This rate is similar to that reported previously for children during open or closed control of mivacurium infusion [4^ -6] . Preliminary data from Woelfel and colleagues [9] suggested similar infusion rates also in infants during halothane anaesthesia, whereas Goudsouzian and Figure 1 Correlation between the age of the paediatric patient and maximum neuromuscular block (NMB) produced by mivacunum 0.1 mg kg" 1 (n = 36). Regression line (95% confidence intervals) shows that the maximum neuromuscular effect of mivacurium is similar at all paediatric ages: r 2 = 0.013; P = 0.5. Data are combined from the present and from our previous study [6] .
colleagues [1, 3] found infusion requirements to be 20-25% less both in infants and children during halothane anaesthesia. Even though young children may require greater infusion rates of mivacurium than older children [6, 10] , it seems that the mean infusion requirement is similar in infants and children. Also, the variability of individual infusion requirements (40 % coefficient of variation) and the range of individual infusion rates (four-fold differences) were similar in the present and in earlier paediatric infusion studies [1, [4] [5] [6] . On the other hand, adults seem to require markedly smaller infusion rates of mivacurium than either infants or children [11] [12] [13] [14] . If the infusion rates of mivacurium are calculated as mg m~2 h" 1 , then infants' requirements are less than those of children or adults.
We determined the hourly infusion requirement for 95 % neuromuscular block as a fraction of an individual ED 95 dose (infusion rate/ED,, dose). The hourly requirement of mivacurium was 6.6 individual ED,, doses. It is of interest that we found a similar value in our previous study in children; these may be derived also for adults [6, 11, 14] . These results suggest that the greater infusion requirements of mivacurium in infancy and childhood are related to the smaller potency of mivacurium in infants and children than in adults [1] [2] [3] 6, [12] [13] [14] [15] . When potency is taken into account, then infants and children require similar amounts of mivacurium per time unit (ED,, doses per hour) as adults.
Goudsouzian and colleagues [1, 3] found that the ED^ dose of mivacurium was less in infants than in children under halothane anaesthesia. Halothane may have affected this result, because dose potency and estimated ED,, doses of mivacurium in the present study were similar to those in our previous study of children of 1-15 yr of age (ED,, doses of 129 vs 139ugkg" 1 ) [6] . We used a similar nitrous oxide-oxygen alfentanil anaesthetic and monitoring conditions, and the same method to estimate an individual ED,, dose [8] for both studies. Figure 1 shows that the maximum neuromuscular block produced by mivacurium 0.1 mg kg"
1 is similar at all [14] . The great individual variability in response to mivacurium has been the subject of debate. Our data showed a wide scatter in response to mivacurium O.lmgkg" 1 ( fig. 1) . However, this dose of mivacurium was clearly less than an ED,, dose (mean maximum response produced was only 76 % neuromuscular block). When individual variability is considered, it should be noted that all neuromuscular blockers have about 20-30 % variability in response. For example, Katz [16] published in 1967 that maximum response to tubocurarine O.lmgkg" 1 varied from 0 to 100% neuromuscular block. If a greater dose is used, then more patients produce 100% neuromuscular block and less variability is present. The routine dose of a neuromuscular blocking agent for tracheal intubation is at least twice the ED,, dose. This indicates that the primary dose of mivacurium in paediatric patients could be 0.25-0.3 mg kg" 1 instead of the recommended maximum single dose of 0.2 mg kg"
The mean onset time of mivacurium 0.1 mg kg ' was 2.1 min in infants. This correlates with our previous regression line for age of child against onset time of mivacurium [6] : mean onset time was shortened from 4.3 min at 15 yr to 2.3 min at 1 yr of age. Infants in the present study were 0.4 yr old and their onset time was close to this regression line (onset time = 0.14 x age in years +2.2 min) [6] . Infants circulate their blood volume in 20-25 s compared with 60 s in older children [17] . This may, in part, explain the short onset time in young infants and children [1, 15] .
